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Abstract
Our group previously demonstrated that administration of a CD34-negative fraction of human non- hematopoietic umbilical
cord blood stem cells (UCBSC) 48 h after ischemic injury could reduce infarct volume by 50% as well as significantly ameliorate
neurological deficits. In the present study, we explored possible mechanisms of action using next generation RNA sequencing
to analyze the brain transcriptome profiles in rats with ischemic brain injury following UCBSC therapy. Two days after
ischemic injury, rats were treated with UCBSC. Five days after administration, total brain mRNA was then extracted for
RNAseq analysis using Illumina Hiseq 2000. We found 275 genes that were significantly differentially expressed after ischemic
injury compared with control brains. Following UCBSC treatment, 220 of the 275 differentially expressed genes returned to
normal levels. Detailed analysis of these altered transcripts revealed that the vast majority were associated with activation of
the immune system following cerebral ischemia which were normalized following UCBSC therapy. Major alterations in gene
expression profiles after ischemia include blood-brain-barrier breakdown, cytokine production, and immune cell infiltration.
These results suggest that UCBSC protect the brain following ischemic injury by down regulating the aberrant activation of
innate and adaptive immune responses.
Keywords
stem cells, human umbilical cord blood, stroke, immunomodulation, neuroinflammation, macrophage, microglia
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Introduction
Each year, over 750,000 individuals in the United States
suffer a stroke, making it a leading cause of morbidity and
mortality. The primary treatment for stroke is administration
of tissue plasminogen activator (tPA). Unfortunately, the
vast majority of stroke victims are unable to reach hospital
emergency rooms within the 3- to 5-h time-window following stroke onset required for effective tPA therapy. Therapies that expand the time window of treatment are therefore
much needed.
We previously isolated a CD34-negative population of
non-hematopoietic umbilical cord blood stem cells
(UCBSC) within human umbilical cord blood that is highly
expandable and exhibit stem cell-like properties1. Systemic
administration of UCBSC 48 h after ischemic brain injury
resulted in a significant reduction in infarct volume and an
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amelioration in neurological severity score as well as limb
placement function in the rat MCAO model of stroke1,2.
Interestingly, very few UCBSC were observed in the brain
28 days post transplantation, suggesting a neurotrophic or
anti-inflammatory function of UCBSC therapy. Indeed, flow
cytometry analysis revealed a reduction in infiltrating
immune cells following ischemic stroke and UCBSC treatment2. The use of stem cells derived from the umbilical cord
blood/matrix have garnered recent attention for their immunomodulatory and neuroprotective properties3–6. Animal
and human studies of ischemic brain injuries demonstrate
that the activation of the immune system and inflammation
are important pathological process following ischemia7–9.
In the present study, we investigated the immunological
mechanisms by which UCBSC exert their neuroprotective
effects, focusing on blood-brain-barrier (BBB)/extracellular
matrix (ECM) function, immune cell infiltration, and secondary apoptosis. We postulate that UCBSC therapy modulates the immune system to reduce the infiltration of
immune cells into the brain following ischemic injury,
thereby reducing secondary injury. To address this issue
we performed RNA sequencing (RNAseq) to study the brain
transcriptome change in rats following ischemic injury and
after the systemic administration of UCBSC.

Materials and Methods
Animal Model of Acute Focal Ischemic Stroke
To induce acute focal transient ischemic stroke, adult Sprague Dawley rats (175.0 + 25.0 g; Groups: Normal, MCAO,
MCAOþUCBSC; n ¼ 5/group) were anesthetized with a
cocktail (0.85 ml/kg) of ketamine (75 mg/ml Ketaject; Phoenix Pharmaceuticals, Burlingame, CA, USA) and xylazine
(10 mg/ml Xyla-ject; Phoenix Pharmaceuticals) intramuscularly. Each rat’s head was stabilized in a Koph head holder
on Stereotaxic Frame (Tujunga, CA, USA) in a supine position after the fur of the neck area was shaved and sterilized.
A midline incision in the skin of the neck was made to
expose subdermal structures. The right common carotid
artery was exposed and traced distally to its bifurcation, the
superficial branch of which is the external carotid artery
(ECA). The right ECA was cauterized and cut to be able
to introduce the thread occluder for the temporary ligation.
The right internal carotid artery (rICA) has an extracranial
branch before it enters the cranium—the pterygopalatine
artery—which was temporarily ligated for a complete
ischemic lesion. The rECA was cut at its distal stem so that
a silicon-coated surgical thread could be inserted into its
lumen. The thread was inserted into the bifurcation, up into
rICA, to occlude the middle cerebral artery (MCAO). The
occluder is kept in place for 1 h before removal. The open
arteries were then cauterized, the wound closed, and the
animal monitored until fully sternal and recovered. All procedures were approved by the IACUC at the University of
Minnesota (Protocol Number: 133-31062A). Considerations
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for the ethical use of animals in this study as well as alternatives to the use of animals were submitted to IACUC prior
to final approval and authorization.

UCBSC Culture
CD34 negative UCBSC were isolated and grown as previous
described1. Briefly, umbilical cord blood was collected after
delivery and, within 4 h, mononuclear cells were separated
by centrifugation at 500  g for 30 min in a Ficoll-hypaque
density gradient (1.077 g/cm3) (Sigma, St. Louis, MO,
USA). The cells were then grown in Dulbecco’s modified
Eagle medium DMEM (Invitrogen, Waltham, MA, USA) /
MCDB-201(Sigma) mix with 10% fetal bovine serum (Invitrogen), 10–4 M of L-ascorbic-acid-2-PO4 (Sigma), 10–9 M of
dexamethasone (Sigma), insulin-transferrin-selenium media
supplement (Sigma), 1 mg/mL of linoleic acid/bovine serum
albumin (Sigma) and 10 ng/ml of epidermal growth factor
(R&D Systems, Minneapolis, MN, USA) and recombinant
human basic fibroblast growth factor (R&D Systems).

Stem Cell Delivery
Two days post-MCAO, animals in the treatment group were
injected with 1 million UCBSC suspended in 500 mL of
sterile saline delivered via saphenous vein under isoflurane
anesthetization. Immunosuppressant drugs (e.g. Cyclosporine A) were not administrated as we have previously
observed beneficial effects of UCBSC therapy in the absence
of immunosuppressive agents10.

Behavioral Testing
Neurological function was assessed by a neurological severity score (NSS) test11 on day 2 and day 7 post-MCAO. The
NSS test consists of eight subtests evaluating motor and
sensorimotor function of the animals’ limbs. Left and right
side limbs were each scored as either 2 (normal function), 1
(impaired function), or 0 (unable to perform). The scores
from these subtests were tallied for the right side and left
side limbs and analyzed using a Student’s t-test.

Tissue Processing and RNA Sequencing
Immediately following NSS testing on day 7, the rats were
deeply anesthetized with ketamine (150 mg/kg). We chose
to do the RNAseq at 7 days because we wished to compare
the transcriptome results with our previous flow cytometry
study2. Rats were then transcardially perfused with phosphate buffer saline and the hemisphere ipsilateral to the
MCAO was isolated. Total RNA was extracted from all 15
brains using the RNeasy Plus Mini Kit (Qiagen, Germantown, MA, USA) according to manufacturer’s instructions.
Each sample was obtained in triplicate (one animal had
duplicate samples only) for a total of 44 total RNA samples
submitted for sequencing.
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RNA samples were analyzed at the University of Minnesota Biomedical Genomics Center. Briefly, total RNA samples were quantified using the RiboGreen fluorometry assay
and RNA integrity was checked using capillary electrophoresis (Agilent BioAnalyzer 2100; Agilent, Santa Clara, CA,
USA). Libraries were generated from 1 mg of total RNA.
Polyadenylated coding mRNA in each sample was isolated
and reverse transcribed using random primers. The resulting
paired-end cDNA libraries were subsequently sequenced
using the HiSeq 2000 (Illumina, San Diego, CA, USA). For
each sample, at least 10 million paired-end reads of 50 base
pairs were performed in four lanes.

Bioinformatics Analysis
FASTQ files for each sample were first combined before
analysis. Raw sequences were analyzed using a customized
pipeline (gopher-pipelines; https://bitbucket.org/jgarbe/
gopher-pipelines/overview) developed and maintained by
the Minnesota Supercomputing Institute. Briefly, quality
controls were performed on each FASTQ files using FastQC
(v0.11.5) before and after adapter trimming with Trimmomatic (v0.33). Post-trimming sequences were aligned to Rattus norvegicus reference genome using HISAT2 (v2.0.2).
Transcript abundance was then estimated using subread
(v1.4.6)12,13. Pathway analysis of differentially expressed
genes was performed by functionally annotating the genes,
performing an overrepresentation enrichment test using
BiNGO package, and visualizing using Cytoscape14.
Read counts generated by subread were filtered to include
genes with counts per million >5 and subsequently analyzed
in R15. The remaining reads were then normalized and log
transformed using edgeR. Heat maps were generated using
the log transformed values with pheatmap package. Hierarchical clustering was performed using Euclidean distances
and average linkage clustering method. Principle component
analysis (PCA) was performed in R using prcomp and visualized using ggplot2 and rgl packages. Immune cell subtype
analysis was performed using CIBERSORT (https://ciber
sort.stanford.edu/) following the recommended settings for
RNA-Seq data. Two-sided Student’s t-test was performed to
assess the CIBERSORT results16. All P-values are listed in
the supplementary files. P-values  0.05 were considered as
significant differences.

Results
UCBSC Therapy Ameliorates Behavioral Deficits
Two days after MCAO, all animals exhibited sensorimotor
deficits assessed by the NSS test. At this time-point, no
significant differences were observed between the two treatment groups (Fig 1). Five days after the systemic administration of UCBSC (7 days post-MCAO), a significant
improvement in NSS score was observed in ischemic rats
treated with UCBSC, relative to untreated ischemic rats
(t-test P ¼ 0.046).
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UCBSC Therapy Globally Diminishes the
Immunological Response to Stroke
To gain insights into the mechanisms of action
underlying UCBSC therapy in ischemic brain injury, we
compared the brain transcriptome in normal, MCAO, and
MCAOþUCBSC rats. After initial filtering, a total of 12,788
genes were used for differential expression (DE) analysis. PCA
shows the MCAO group is clearly clustered separate from both
control and MCAOþUCBSC treatment groups (Fig 1A–C).
Plotting DE genes of MCAO or MCAOþUCBSC against
gene expression levels of the normal brain further depicts a
separation of untreated MCAO transcripts (Fig 2A). Relative
to the control brain, the MCAO group had 275 DE genes
(4 downregulated, 271 upregulated; Fig 2B; Supplementary
Table ST1). After UCBSC treatment, 220 of the 275 genes that
were initially altered following MCAO returned to normal
levels (Fig 2B; Supplementary Table ST2). Among the 55
genes that remain DE, 42 show a trend shifting towards normal
levels (Fig 2B). Among the 4 genes initially downregulated
after MCAO, only the Pdcd5 gene returned to normal levels
after UCBSC treatment. Relative to control rats, treatment of
ischemic rats with UCBSC results in normalization of the gene
expression profile (Supplementary Table ST3). A total of 101
genes were DE (19 downregulated, 82 upregulated) between
the two groups. We then used gene ontology enrichment
analysis to analyze alterations to the function of these DE
genes. The downregulated genes showed no significant pathway enrichment; however, the pathways of the 220 upregulated
genes showed enrichment in numerous pathways related to
immune system processes, and immune cell activations suggesting UCBSC treatment effectively diminishes immune
response caused by MCAO (Supplementary Fig 1; Supplementary Table ST4).

UCBSC Therapy Normalizes Gene Transcripts Related
to BBB and ECM Function
Because the breakdown of the extracellular matrix (ECM)
and blood-brain-barrier (BBB) allows immune cells to penetrate into the brain following ischemic injury, we specifically
investigated genes related to the BBB functions (Fig 3A;
Supplementary Table ST5, 6). We also identified genes associated with extracellular matrix (GO:0031012) from the
Gene Ontology Consortium (Fig 3B). The results show most
genes associated with BBB and ECM were upregulated following MCAO treatment and normalized by treatment with
UCBSC (Supplementary Table ST5, 6).

UCBSC Therapy Reduces Apoptotic Gene Transcripts
To assess if UCBSC can reduce cell death after MCAO, we
investigated genes related to apoptosis. We identified genes
associated with the regulation of apoptotic process
(GO:0042981) from the Gene Ontology Consortium. The
results show most genes associated with apoptosis were
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Fig 1. UCBSC therapy ameliorates neurological deficits induced by MCAO. (A) The Neurological Severity Scores (NSS) were similar for the
two groups of animals 2 days post MCAO but prior to the UCBSC therapy. Five days after UCBSC cell therapy (day 7 after MCAO), NSS
scores improved significantly in the UCBSC treated group (t-test P ¼ 0.046). (B, C, and D) PCA of RNA-seq data show MCAO-treated
samples cluster separately from Normal and MCAOþUCBSC groups.

upregulated following MCAO treatment and normalized
with UCBSC therapy (Fig 3C; (Supplementary Table ST7).

UCBSC Therapy Normalizes Gene Transcripts Related
to Cytokine Production
Cytokines are involved in stroke-induced cerebral inflammation. We identified genes associated with regulation of cytokine production (GO:0001817) from the Gene Ontology
Consortium plotted as a heatmap (Fig 3D). Results demonstrate many genes associated with pro-inflammatory cytokines were upregulated following MCAO treatment and
normalized by UCBSC (Supplementary Table ST8).

UCBSC Therapy Returns Immune Cell Subtypes to
Normal Levels
We next investigated the immune cell infiltration after
MCAO using CIBERSORT with the lm22 immune gene

signature set (Fig 4). The absolute score estimated by
CIBERSORT show significantly increased immune cell
infiltration after MCAO (0.97 vs. 0.47; MCAO vs. Control;
two-sided t-test P ¼ 0.039). An intermediate effect of
UCBSC was observed where treated animals were not statistically significant from MCAO (0.97 vs. 0.60; MCAO vs.
MCAOþUCBSC; P ¼ 0.126) nor controls (0.47 vs. 0.60;
Control vs. MCAOþUCBSC; P ¼ 0.160).
Deeper analysis among the subtypes of immune cell and
inflammatory cell within the CIBERSORT identified a significant increase in transcripts specific for monocytes, resting
dendritic cells, CD8- and naive CD4-T cells, as well as a
decrease in transcripts specific for M2 macrophages following
MCAO, relative to controls. Gene transcripts associated with
neutrophils (Fig 5A), natural killer cells (Fig 5B), microglia/
macrophages (Fig 5C), B-cells (Fig 5D), mast cells (Fig 5E),
CD4 T-cells (Fig 5F) and regulatory T-cells (Fig 5G) were
significantly increased after MCAO, and UCBSC therapy
reversed these transcripts back to normal levels.

868

Cell Transplantation 28(7)

Fig 2. Gene expression analysis following MCAO and UCBSC treatment. (A) Scatter plot of significantly DE genes that return to normal
expression levels after UCBSC treatment. Black dotted line represents expression levels of transcripts from normal brain. Red dots are
expression levels of transcripts from MCAO group. Aqua colored circles are expression levels of transcripts after UCBSC treatment. X-axis
indicates log10 counts per million (cpm) level from normal brain. Y-axis represents corresponding expression levels for the same transcript
from MCAO group or UCBSC group. (B) Gene expression patterns following MCAO and UCBSC treatment.

Discussion
2

Consistent with our previously published reports , the data
presented here suggest UCBSC is an effective treatment for
ischemic stroke and acts through modulation of the immune
system. We hypothesize that a breakdown of the BBB and
ECM results in increased infiltration of immune cells, leading to secondary damage at the site of infarction. We
observed that UCBSC treatment rescued sensorimotor deficits following stroke and systematically normalized gene
expression alterations caused by MCAO. Our results suggest
the underlying mechanism of UCBSC treatment in protecting the brain following a stroke is through dampening the
immune response and immune cell infiltration. These
changes are consistent with reports by other investigations
on ischemic brain injury17–20.

Stroke and BBB/ECM Function
The initial pathophysiological processes that permit the
penetration of immune cells into the brain parenchyma following ischemic injury is the breakdown of the BBB and
ECM. Cell adhesion molecules engage immune cells and
initiate their penetration across the BBB21. After cerebral
ischemia, we observed an upregulation in the expression of
ICAM1, which is part of the immunoglobulin superfamily,
and is involved in many processes including inflammation,
immune responses and intracellular signaling. Immediately
following ischemia, ICAM1 expression is localized to

capillary endothelium of intra-parenchymal blood vessels,
but expression is increased in leukocytes in the weeks following22–24. Interestingly, cell-surface expression levels of
ICAM1 correlated with infiltration of CD4 þ or effector
memory T-cells25, suggesting that modulation of ICAM1
expression by UCBSC may play a role in the observed
reduction in infiltrating immune cells. Preclinical treatment
of ischemia with anti-ICAM1 antibodies reduced edema
and infarct size26, although this effect was not translated
into the clinic27.
Matrix metalloproteinase (MMP) enzymes are responsible for the breakdown of the ECM by degrading tight junctions and basal lamina proteins, leading to immune cell
infiltration28. We observed an upregulation of transcripts
of several MMPs (including -2, -8, -12, -14, and -19) at 7
days post-ischemia that was normalized with UCBSC treatment. In rodent models of cerebral ischemia, elevation of
MMP-2, MMP-8, and MMP-14 have been observed29–31.
Interestingly, an increase in expression of MMP regulator
Timp1 was observed in untreated ischemic animals, suggesting that BBB damage has peaked and vascular remodeling
may begin31. Further investigation is warranted to determine
if UCBSC treatment inhibits BBB breakdown or mediates
rapid vascular repair.

Cytokine/Chemokine Modulation
Through gene ontology, we identified DE genes in our dataset associated with cytokine and chemokine production.
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Fig 3. Heatmap of (A) BBB, (B) ECM, (C) apoptosis, and (D) cytokine associated genes. The expression pattern of these genes return to
normal expression levels after UCBSC treatment. Red indicates relative increase in expression and blue indicates relative decrease in
expression.

Specifically, we observed an upregulation of Tgf-b1 and
many interleukin receptors in ischemic rats 7 days following
MCAO. The increased expression of Tgf-b1 is likely driven
by the increase in macrophages and microglia at the site of
infarction, as previous studies have demonstrated increased
colocalization of Tgf-b1 signaling in Cd68 þ cells32. Other
cytokine specific DE genes we observed to be upregulated
following MCAO include Ccl2, Hmox1, TLR2, Serpine1,
and C3ar1. Similarly, increase expression of chemokines
Pycard, Tlr4, Il4ra, Tlr7, and Csfl1r were increased in
untreated MCAO rats. These cytokines and chemokines are
likely to be upregulated due to the migration of microglia at

the site of infarction33. Given the complex interactions and
kinetics between the many pro- and anti-inflammatory cytokines and their receptors following injury, it is difficult to
determine the possible mechanisms at a single time-point.
However, possible sites of action may include the spleen,
cervical lymph nodes, and other lymphoid organs where
UCBSC may interact with immune cells.

Modulation of the Immune Cell Infiltration
Using the CIBERSORT analysis package, we were able to
quantify transcripts associated to individual immune-cell
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at 3 days post-ischemia, which remained elevated at 12-fold
normal levels on day 737. In the normal brain, CD4 þ and
CD8 þ cytotoxic T cell lymphocytes cells are present at low
levels; however, after ischemic injury, there is a dramatic
influx of CD4 þ cells, which can activate resident brain
microglia and upregulate endothelial cell adhesion molecules, increasing BBB permeability40–42. Perhaps through
UCBSC treatment following MCAO, a normalization of the
pro-recovery M2 macrophages/microglia is able to reduce
inflammation, thereby reducing infiltration of peripheral
adaptive immune cells. Further work is needed to determine
the kinetics of inflammation following UCBSC therapy.

Ischemic Cascade

Fig 4. CIBERSORT analysis of control, MCAO, and UCBSC treatment. The relative percentage of different immune cell types were
deconvoluted from the RNA-seq data using CIBERSORT.

subtypes. Similar to our previous study interrogating inflammation through flow cytometry within the ischemic hemisphere, we observed increased transcripts associated with
innate immune system cells – NK cells, neutrophils, monocytes/macrophages, and resting dendritic cells; and cells
associated with the adaptive immune system – CD8-T cells
and naive CD4 þ T-cells, and B-cells. In addition, a decrease
in pro-recovery M2 macrophages was observed. The activation of the innate immune system triggered immediately
after ischemic stroke and is manifested by the mobilization
of NK cells, neutrophils, resident macrophages, and microglia infiltrating the infarct zone within minutes after ischemia34,35. In untreated MCAO rats we observed increased
expression in genes (including Trem2, Csf1, and Irf8) that
have been associated with activation and proliferation of
microglia33,36.
Infiltration of peripheral immune cells into the site of
infarction also plays an important role in the outcome of
ischemia. Within 1 h, antigen presenting dendritic cells infiltrate the ischemic brain37–39. In the ischemic brain hemisphere, a 20-fold elevation of dendritic cells was observed

In addition to neuronal death via necrosis or immune cell
infiltration, secondary apoptosis occurs in the oxygendeprived penumbra surrounding the initial infarct zone20.
We observed that transcripts related to apoptosis were upregulated following ischemic injury, specifically, Scamp2,
Cebpa, Shc1, Sipa1, Tep1, Ucp2, Dap, Plp2, Ccnb1, and Sla.
Furthermore, treatment with UCBSC seemed to restore these
transcripts to control levels.
A previous study showed Cyclin-B1 (Ccnb1) to be upregulated and cytotoxic following ischemia through excitotoxicity43. Other cell cycle-related genes we found to be
upregulated following ischemia were Cebpa, Acer2, and
Tep1. The increased expression of these genes suggests that
cell proliferation mechanisms are upregulated following
ischemia. This upregulation may result from glial, immune
cell, or neuronal proliferation, but this question needs to be
pursued further.
Reactive oxygen species (ROS) expression in the periinfarct region has been shown to induce apoptosis following
ischemia20. Inhibition of SHC1 following ischemia in rats
has decreased infarct size, as well as penumbra-associated
apoptosis, likely through a decrease in ROS creation44,45. In
our study, we found that UCBSC lower the expression of
SHC1 to non-infarct control levels, suggesting these UCBSC
may decrease ROS production, thus preventing apoptosis
induction.

Conclusion
In summary, we provide a systems approach to study the
cellular mechanisms underlying the neuroprotective effects
of UCBSC treatment for ischemic brain injury. Our transcriptomics analysis reveal UCBSC are able to reduce upregulation of transcripts associated with BBB permeability,
thereby reducing infiltration and activation of immune cells,
which we believe is responsible for the downregulation of
apoptotic related genes. These data further suggest that the
UCBSC therapy is modulating the microglia/macrophage
population to promote a pro-recovery M2 phenotype. This
modulation of the immune system occurs even when the
UCBSC are administered 2 days after the ischemic injury,
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Fig 5. Box plot showing RNA expression levels change of (A) Neutrophil, (B) Natural Killer cell, (C) Macrophage, (D) B-cell, (E) Mast cell,
(F) T-cell, and (G) Regulatory T-cell related gene transcripts after MCAO (Red) and UCBSC treatment (Green). * denotes statistical
significance between the three groups P < 0.05 (edgeR, false-discovery-rate adjusted).

significantly expanding the therapeutic window currently
available for tPA treatment. This study provides insights into
understanding the cellular mechanisms of stroke and its
treatment with UCBSC. The cellular mechanisms underlying
the therapeutic benefit of these stem cells provides a basis for
future clinical studies evaluating the safety and efficacy of
these cells in treating patients with ischemic brain injury.
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